Published on Web 08/31/2002
Enantioselective Synthesis of the Protein Phosphatase
Inhibitor (-)-Motuporin
Tao Hu and James S. Panek*,†
Contribution from the Department of Chemistry, Metcalf Center for Science and Engineering,
590 Commonwealth AVenue, Boston UniVersity, Boston, Massachusetts 02215
Received May 9, 2002
Abstract: A highly convergent asymmetric synthesis of the protein phosphatase inhibitor motuporin 1a is
described. Synthesis and coupling of the individual peptide fragments [34 + 35 f 51] followed by
macrocyclization afforded the fully protected motuporin precursor 33, which is converted to the natural
product by dehydration and ester hydrolysis. Six of the eight stereogenic centers associated with the natural
product were introduced using asymmetric crotylsilane bond construction methodology. Our approach
features an efficient Pd(0)-catalyzed cross-coupling reaction between a configurationally well-defined vinyl
zinc intermediate 22 and an (E)-vinyl iodide 7, which afforded compound 43, resulting in the construction
of the trisubstituted (E,E)-diene system of the motuporin side chain. Improved reaction conditions for
macrocyclization in the formation of 33 are also detailed.
(PP2A).11 In vivo, these compounds have been reported to
promote tumor formation,12 suppress cell transformation,13 or
Introduction
It is now widely accepted that modulation of the reversible
phosphorylation of proteins, as catalyzed by protein kinases
(PKs) and protein phosphatases (PPs), is the principal mecha-
nism by which eukaryotic cells respond to external stimuli.1
The balance between phosphorylated and dephosphorylated
proteins, which is controlled by the protein kinase and phos-
phatase activities, is crucial to maintaining proper cellular
function.2 Excessive protein phosphorylation, whether through
the activation of kinases or through the inhibition of phos-
phatases, can lead to uncontrolled cellular proliferation, sug-
gesting the possibility of an active role for the phosphatases in
tumor suppression.3 The controlled disruption of this balance
through the use of PPs inhibitors is a method by which one can
dissect this complex system.
There is a diverse group of structurally interesting natural
products that act by inhibiting certain phosphatases, thereby
disrupting the normal biochemical pathway. Examples include
okadaic acid,4 tautomycin,5 calyculin,6 cantharidine,7 micro-
cystins,8 nodularins,9 and motuporin,10 all of which are potent
competitive inhibitors of two major classes of phosphatases,
protein phosphatase 1 (PP1), and protein phosphatase 2A
induce apoptosis,14 depending on length of exposure and the
cell type.
Motuporin (1a) is a cyclic pentapeptide isolated in 1992 by
Andersen and co-workers from the marine sponge Theonella
swinhoei Gray collected in Papua New Guinea.10 This molecule
is one of the most potent PP1 inhibitors known, inhibiting at
sub-nanomolar concentrations (IC50 < 1.0 nM) and showing
strong in vitro cytotoxicity against a variety of human cancer
cells. The structures of motuporin and cyanobacterial derived
natural product nodularin (1b) show remarkable resemblance
to each other. Specifically, these cyclic peptides contain the
unusual â-amino acid (2S,3S,8S,9S,4E,6E)-3-amino-9-methoxy-
2,6,8-trimethyl-10-phenyldeca-4,6-dienoic acid (Adda),9b an R,â-
unsaturated amino acid N-methyldehydrobutyrine (N-Me∆But),
an isolinked D-glutamate, and a â-methyl D-aspartate (â-MeAsp)
residue (Figure 1).
Motuporin was isolated later than other members of its class
and is derived from a much less readily accessible source.
(8) (a) Botes, D.; Tuinman, A.; Wessels, P.; Viljoen, C.; Kruger, H.; Williams,
D. H.; Santikarn, S.; Smith, R.; Hammond, S. J. Chem. Soc. Perkin Trans.
1 1984, 2311-2318. (b) Painuly, P.; Perez, R.; Fukai, T.; Shimizu, Y.
Tetrahedron Lett. 1988, 29, 11-14.
* To whom correspondence should be addressed. E-mail: Panek@
chem.bu.edu.
(9) (a) Botes, P. B.; Wessels, P. L.; Kruger, H.; Runnegar, M. T. C.; Santikarn,
S.; Smith, R. J.; Barna, J. C. J.; Williams, D. H. J. Chem. Soc. Perkin
Trans. 1 1985, 2747-2748. (b) Rinehart, K. L.; Harada, K.; Namikoshi,
M.; Chen, C.; Harvis, C. A.; Munro, M. H. G.; Blunt, J. W.; Mulligan, P.
E.; Beasley, V. R.; Dahlem, A. M.; Carmichael, W. W. J. Am. Chem. Soc.
1988, 110, 8557-8558.
† Recipient of a 2002 Arthur C. Cope Scholar Award.
(1) Hunter, T. Cell 1995, 80, 225-236.
(2) Mehrotra, A. P.; Webster, K. L.; Gani, D. J. Chem. Soc., Perkin Trans. 1
1997, 2495-2511.
(3) (a) Cohen, P.; Cohen, P. T. W. J. Biol. Chem. 1989, 264, 21435-21438.
(b) Krebs, E. G. Angew. Chem., Int. Ed. Engl. 1993, 32, 1122-1129.
(4) Tachibana, K.; Scheuer, P. J.; Tsukitani, Y.; Kikuchi, Y.; Van Engen, D.;
Clardy, J.; Gopichand, Y.; Schmitz, F. J. J. Am. Chem. Soc. 1981, 103,
2469-2471.
(10) Dilip de Silva, E.; Williams, D. E.; Andersen, R. J.; Klix, H.; Holmes, C.
F. B.; Allen, T. M. Tetrahedron Lett. 1992, 33, 1561-1564.
(11) Takai, A.; Sasaki, K.; Nagai, H.; Mieskes, G.; Isobe, M.; Isobe, M.; Isons,
K.; Yasumoto, T. Biochem. J. 1995, 306, 657-662.
(12) Nishiwaki, M. R.; Ohta, T.; Nishiwaki, S.; Suganuma, M.; Kohyama, K.;
Ishikawa, T.; Carmichael, W. W.; Fujiki, H. J. Cancer Res. Clin. Oncol.
1992, 118, 420-424.
(5) Cheng, X. C.; Ubukata, M.; Isono, K. J. Antibiot. 1990, 43, 809-819.
(6) Kato, Y.; Fusetani, N.; Matsunaga, S.; Hashimoto, K.; Fujita, S.; Furuya,
T. J. J. Am. Chem. Soc. 1986, 108, 2780-2881.
(7) Li, Y. M.; Casida, J. E.; Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 11867-
11870.
(13) Mordon, L. J. Science 1991, 251, 142-143.
(14) Boee, R.; Gjertsen, B. T.; Vintermyr, O. K.; Houge, G.; Lanotte, M.;
Doeskeland, S. O. Exp. Cell Res. 1991, 195, 237-246.
9
11368
J. AM. CHEM. SOC. 2002, 124, 11368-11378
10.1021/ja0206700 CCC: $22.00 © 2002 American Chemical Society